Cargando…

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson's disease

Detalles Bibliográficos
Autores principales:	Stayte, Sandy, Vissel, Bryce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137258/ http://dx.doi.org/10.3389/fnins.2014.00254

Ejemplares similares

Advances in non-dopaminergic treatments for Parkinson's disease
por: Stayte, Sandy, et al.
Publicado: (2014)

New hope for devastating neurodegenerative disease
por: Stayte, Sandy, et al.
Publicado: (2017)

Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease
por: Stayte, Sandy, et al.
Publicado: (2015)

Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on l-Dopa induced dyskinesia
por: Rentsch, Peggy, et al.
Publicado: (2019)

Parafascicular Thalamic and Orbitofrontal Cortical Inputs to Striatum Represent States for Goal-Directed Action Selection
por: Stayte, Sandy, et al.
Publicado: (2021)

Editorial: Non-Dopaminergic Systems in Parkinson’s Disease
por: Miguelez, Cristina, et al.
Publicado: (2020)

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Parkinson’s disease, dopaminergic drugs and the plant world
por: Kempster, Peter, et al.
Publicado: (2022)

Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo
por: Stayte, Sandy, et al.
Publicado: (2017)

Advances in Alzheimer’s disease’s pharmacological treatment
por: Conti Filho, Carlos Elias, et al.
Publicado: (2023)

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
por: Schintu, Nicoletta, et al.
Publicado: (2020)

Corrigendum: Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease with a deep learning algorithm
por: Yan, Yu-Chen, et al.
Publicado: (2023)

Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease
por: Mao, Qi, et al.
Publicado: (2020)

Fyn Kinase-Mediated PKCδ Y311 Phosphorylation Induces Dopaminergic Degeneration in Cell Culture and Animal Models: Implications for the Identification of a New Pharmacological Target for Parkinson’s Disease
por: Saminathan, Hariharan, et al.
Publicado: (2021)

Corrigendum: Pharmacological activity and clinical use of PDRN
por: Squadrito, Francesco, et al.
Publicado: (2022)

Corynoxine Protects Dopaminergic Neurons Through Inducing Autophagy and Diminishing Neuroinflammation in Rotenone-Induced Animal Models of Parkinson’s Disease
por: Chen, Leilei, et al.
Publicado: (2021)

Advances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases
por: Yu, Linyuan, et al.
Publicado: (2023)

Echinacoside Protects Dopaminergic Neurons Through Regulating IL-6/JAK2/STAT3 Pathway in Parkinson’s Disease Model
por: Yang, Xueping, et al.
Publicado: (2022)

Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease
por: Luo, Yunxia, et al.
Publicado: (2023)

Corrigendum: Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carcinoma via network pharmacology and experimental validation
por: Liu, Minglu, et al.
Publicado: (2023)

Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson’s disease
por: Yan, Yu-Chen, et al.
Publicado: (2022)

Corrigendum: Circadian Pharmacological Effects of Paeoniflorin on Mice With Urticaria-like Lesions
por: Peng, Li, et al.
Publicado: (2022)

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
por: Ray Chaudhuri, K, et al.
Publicado: (2016)

The Underlying Mechanism of Paeonia lactiflora Pall. in Parkinson’s Disease Based on a Network Pharmacology Approach
por: Du, Wanqing, et al.
Publicado: (2020)

Corrigendum: Review of phytomedicine, phytochemistry, ethnopharmacology, toxicology, and pharmacological activities of Cymbopogon genus
por: Tibenda, Jonnea Japhet, et al.
Publicado: (2022)

Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases
por: Cavalli, Giulio, et al.
Publicado: (2019)

Effect of Dopaminergic Medication on Postural Sway in Advanced Parkinson’s Disease
por: Revilla, Fredy J., et al.
Publicado: (2013)

Advances in optical imaging for pharmacological studies
por: Arranz, Alicia, et al.
Publicado: (2015)

Advances in Neurobiology and Pharmacology of GPR12
por: Allende, Gonzalo, et al.
Publicado: (2020)

Recent advances in voltage-gated sodium channels, their pharmacology, and related diseases
por: Desaphy, Jean-François, et al.
Publicado: (2013)

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
por: Wang, Yumin, et al.
Publicado: (2021)

Endocannabinoid Modulation of Dopaminergic Motor Circuits
por: Morera-Herreras, Teresa, et al.
Publicado: (2012)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Corrigendum: Research advances in drug therapy of endometriosis
por: Shi, Jianyou, et al.
Publicado: (2023)

Corrigendum: Research advances in drug therapy of endometriosis
por: Shi, Jianyou, et al.
Publicado: (2023)

Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-κB Pathway in Parkinson’s Disease
por: Gan, Ping, et al.
Publicado: (2020)

Pharmacological and Biochemical Interventions of Cigarette Smoke, Alcohol, and Sexual Mating Frequency on Idiopathic Rat Model of Parkinson's Disease
por: Ambhore, NS, et al.
Publicado: (2012)

Commentary: A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease
por: Muñoz, Patricia, et al.
Publicado: (2016)

Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease
por: Taximaimaiti, Reyisha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5qcmm22av6sc91espr906vf87l